Venous Thromboembolism Anticoagulation Duration Decision — free guideline decision tool
This tool decides whether VTE anticoagulation stops at 3 months or extends, weighing recurrence risk (by provoking factor) against bleeding risk.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Provoking-factor type | Major transient (surgery/trauma/prolonged immobilization) |
|---|---|
| Bleeding risk | Low-moderate |
→Anticoagulation durationStop anticoagulation after 3 months
- Decision：Caused by a major transient factor (surgery, trauma, prolonged immobilization), the recurrence risk after stopping is low, and 3 months suffices.
- General rule：All VTE is anticoagulated at least 3 months; those on extended anticoagulation should periodically (e.g. yearly) reassess bleeding risk, benefit, and patient preference
- Bleeding risk：Low-moderate bleeding risk: can tolerate extended anticoagulation
| Provoking-factor type | Recurrent VTE |
|---|---|
| Bleeding risk | High |
→Anticoagulation durationExtended/indefinite anticoagulation
- Decision：Recurrent VTE (especially unprovoked) carries high recurrence risk, and extended or indefinite anticoagulation is recommended.
- General rule：All VTE is anticoagulated at least 3 months; those on extended anticoagulation should periodically (e.g. yearly) reassess bleeding risk, benefit, and patient preference
- Bleeding risk：High bleeding risk: favors a fixed 3-month course
Common questions
What is Venous Thromboembolism Anticoagulation Duration Decision?
This tool decides whether VTE anticoagulation stops at 3 months or extends, weighing recurrence risk (by provoking factor) against bleeding risk.
How is Venous Thromboembolism Anticoagulation Duration Decision calculated? What is the core formula?
Major transient → 3 months. Minor transient → ≥ 3 months, individualized. Cancer → until inactive. Recurrent → extended/indefinite. Unprovoked → extended if low-moderate bleeding (reduced-dose DOAC), stop at 3 months if high bleeding.
When is Venous Thromboembolism Anticoagulation Duration Decision used?
Use to set anticoagulation duration: short course for major transient triggers, indefinite for cancer or recurrence, and bleeding-risk-dependent for unprovoked VTE.
What are the key clinical points for Venous Thromboembolism Anticoagulation Duration Decision?
Unprovoked VTE tips toward extended anticoagulation unless bleeding risk is high, where a 3-month course with possible aspirin is preferred. (original synthesis · not guideline verbatim) All VTE receives at least 3 months of anticoagulation regardless of provoking factor. Extended courses are periodically reassessed for bleeding risk, benefit, and preference.
What are the limits and cautions when using Venous Thromboembolism Anticoagulation Duration Decision?
For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
How is Venous Thromboembolism Anticoagulation Duration Decision calculated in practice? Can you show a worked example?
Inputs: Provoking-factor type Major transient (surgery/trauma/prolonged immobilization), Bleeding risk Low-moderate → Result: Anticoagulation duration Stop anticoagulation after 3 months（Decision: Caused by a major transient factor (surgery, trauma, prolonged immobilization), the recurrence risk after stopping is low, and 3 months suffices., General rule: All VTE is anticoagulated at least 3 months; those on extended anticoagulation should periodically (e.g. yearly) reassess bleeding risk, benefit, and patient preference, Bleeding risk: Low-moderate bleeding risk: can tolerate extended anticoagulation） Inputs: Provoking-factor type Recurrent VTE, Bleeding risk High → Result: Anticoagulation duration Extended/indefinite anticoagulation（Decision: Recurrent VTE (especially unprovoked) carries high recurrence risk, and extended or indefinite anticoagulation is recommended., General rule: All VTE is anticoagulated at least 3 months; those on extended anticoagulation should periodically (e.g. yearly) reassess bleeding risk, benefit, and patient preference, Bleeding risk: High bleeding risk: favors a fixed 3-month course）
Run Venous Thromboembolism Anticoagulation Duration Decision now
This tool decides whether VTE anticoagulation stops at 3 months or extends, weighing recurrence risk (by provoking factor) against bleeding risk.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.